No Data
Changjiang Pharmaceutical Group (300391.SZ): Its main business includes traditional Chinese medicine decoction pieces, pharmaceutical wholesale, photovoltaic equipment, etc.
Grainews, November 12th ︱ Changjiang Pharmaceutical Group (300391.SZ) stated on the investor interaction platform that the company's main business currently includes traditional chinese medicine decoctions, pharmaceutical wholesales, photovoltaic equipment, etc. In addition, the company's subsidiary Ningxia Changjiang Pharmaceutical Liangsheng has launched various tea drinks and medicinal food homologous products, including 15 liver-nourishing teas with authentic Chinese wolfberry and astragalus as the formula, 20 damp-dispelling teas, 9 Eight Treasures teas, as well as compressed confectioners and other medicinal food homologous varieties.
Changyao Holdings: Report for the third quarter of 2024
changjiang pharmaceutical group (300391.SZ): net loss of 0.181 billion yuan in the first three quarters.
On October 29, Gelonhui reported that Changjiang Pharmaceutical Group (300391.SZ) released its third quarter report for 2024, achieving revenue of 0.101 billion yuan in the first three quarters of the year, a year-on-year decrease of 90.12%; net income attributable to the shareholders of the listed company was -0.181 billion yuan; net income attributable to the shareholders of the listed company after deducting non-recurring gains and losses was -0.179 billion yuan; basic earnings per share was -0.5166 yuan.
A-share traditional chinese medicine stocks rise, Changjiang Pharmaceutical Group's stock price rises more than 7%.
Gelonghui on October 24th | Changjiang Pharmaceutical Group rose more than 7%, Datang Pharmaceutical, Biogateway, chengdu Huasun Technology Group Inc., Ltd., teyi pharmaceutical group, *Special Treat Dadi Pharmaceutical, Guiyang Xintian Pharmaceutical and others also followed the rise.
Express News | Changjiang Pharmaceutical Group: Director Li Xuan resigns due to personal reasons.
Changyao Holdings: 2024 Semi-Annual Report Summary
No Data
No Data